newsfilter
← Latest News
GlobeNewswire·

Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity

WILMINGTON, Del., May 12, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension